Large-scale trial results indicate that Novo-Nordisk A/S's weight loss drug Ozempic is related to rare visual loss, supporting the research findings released earlier this year by Harvard University. Obese patients using Ozempic are over twice as likely to be diagnosed with NAION. NAION occurs when decreased blood flow injures the optic nerve. The risk of the eye condition remains low; patients should remain vigilant. Novo-Nordisk A/S's stock in Denmark once fell by more than 3.3%.
最新研究结果支持哈佛的发现：诺和诺德减肥药Ozempic与罕见的视觉损失有关
The latest research results support Harvard's findings: Novo-Nordisk A/S's weight loss drug Ozempic is associated with rare visual loss.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated